<p>Dr Richard Pither, CEO, Cytox Ltd: At Cytox, Richard has spent 25 years in the Alzheimer&#8217;s disease field and is focused on developing novel genetic tests for assessing Alzheimer’s Disease risk. The genoSCORE test, developed in partnership with Thermo Fisher Scientific and Sampled, is aimed at clinicians assessing patients at risk of cognitive decline due to Alzheimer’s disease in addition to Pharma companies seeking high risk patients for recruitment into clinical trials. Over the past 25 years, Richard has developed diagnostic and therapeutic products for GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. Richard’s academic training is from Bristol University (UK) and Harvard Medical School.</p>
<p>&nbsp;</p>
